Abstract In this study we identified two heterocyclic compounds (5 and 6) as potent and specific inhibitors of CK1d (IC 50 = 0.040 and 0.042 lM, respectively). Whereas compound 5 exhibited fivefold higher affinity towards CK1d than to CK1e (IC 50 CK1e = 0.199 lM), compound 6 also inhibited CK1e (IC 50 = 0.0326 lM) in the same range as CK1d. Selected compound 5 was screened over 442 kinases identifying 5 as a highly potent and selective inhibitor of CK1d. X-ray analysis of 5 bound to CK1d demonstrated its binding mode. In addition, characterization of 5 and 6 in a cell biological approach revealed the ability of both compounds to inhibit proliferation of tumor cell lines in a dose and cell line specific manner. In summary, our optimizations lead to the development of new highly selective CK1d and e specific inhibitors with biological activity.
Introduction
Protein kinases in general represent attractive targets for drug development. Recently, interest in specifically targeting members of the casein kinase 1 (CK1) family, a highly conserved ubiquitously expressed serine/threonine protein kinase family, has increased enormously (Knippschild et al. 2005a ). The seven mammalian isoforms CK1a, b, c 1 , c 2 , c 3 , d and e and their various splice variants are all highly conserved within their kinase domains (*290 residues), but differ significantly within their regulatory N-terminal and C-terminal domains. CK1 isoforms can be regulated by inhibitory autophosphorylation mainly occurring within their C-terminal domains, site-specific phosphorylation mediated by cellular kinases, dephosphorylation of autophosphorylation sites, cleavage of the C-terminal domain, and subcellular compartmentalization (Giamas et al. 2007; Knippschild et al. 2005a ). CK1 isoforms phosphorylate many different substrates bearing either a canonical or a non-canonical consensus sequence. They are involved in the regulation of many different cellular processes such as canonical Wnt signaling, DNA damage response, cell cycle progression, apoptosis and chromosome segregation (Cheong and Virshup 2010; Price 2006; Knippschild et al. 2005a, b) . Since deregulation of CK1 isoforms have been linked to the development of various types of disorders such as cancer (CK1a/c/d/e), neurodegenerative diseases (CK1d), and inflammatory disorders (CK1a/d/e), the use of CK1 (isoform)-specific inhibitors may have therapeutic potential in the cure of these diseases (Gill et al. 2007; Knippschild et al. 2005a; Lin and Peng 2006; Perez et al. 2010) .
So far, several CK1-specific inhibitors have been identified, among them IC261 and D4476 (Mashhoon et al. 2000; Rena et al. 2004 ). However, permeability to the cell membrane for most available CK1 inhibitors is weak, and their use in vivo restricted. Therefore, efforts are ongoing to identify new potential CK1-specific inhibitors with IC 50 values in the low nanomolar range which can be used in pharmacological studies and might be effective as therapeutic drugs.
Previously we identified piperidinyl-thiazoles as inhibitors of nuclear factor kappa B (NFjB) (Leban et al. 2007 ). The well-characterized NFjB is a key player in the signal transduction of severe diseases such as muscular dystrophy, obesity, atherosclerosis, cystic fibrosis, arthritis, Crohn's disease, sepsis, rheumatic disease and cancer (Baghdiguian et al. 1999; Li et al. 2008; Peterson and Guttridge 2008; Bamborough et al. 2010; Demer and Tintut 2011; Nichols et al. 2008; Criswell 2010; Li et al. 2009; Wei and Feng 2010; Gil et al. 2007 ).When we deleted the piperidinyl residue the compound series described here was obtained. This series exhibited only modest NFjB inhibitory activity (data not shown) but showed significant inhibition of CK1 family members in a selectivity screen comprising 442 eukaryotic protein kinases.
Materials and methods

Intermediate synthesis
Ethyl 2-(2-(trifluoromethoxy)benzamido)thiazole-4-carboxylate
To a solution of ethyl 2-aminothiazole-4-carboxylate (12 g, 70 mmol, 1 eq.) in dry THF (300 ml) N,N-diisopropylethylamine (250 ml, 209 mmol, 3 eq.) was added. A solution of 2-(trifluoromethoxy)-benzoyl chloride (19 g, 84 mmol, 1.2 eq.) in THF (50 ml) was added dropwise at 0°C. The reaction mixture was stirred for 24 h at room temperature. Water (50 ml) was added and THF was removed under reduced pressure. The residue was extracted with DCM. The organic layer was dried over MgSO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (PE/ EtOAc 80:20). The product was obtained as a white solid (12 g, 33 mmol, 48% yield).
1 H NMR (400 MHz, DMSO-d 6 ): d (ppm) = 1.30 (t, J = 7.1 Hz, 3H), 4.29 (q, J = 7.1 Hz, 2H), 7.49-7.59 (m, 2H), 7.71 (dt, J = 7.8, 1.7 Hz, 1H), 7.79 (dd, J = 7.79, 1.7 Hz, 1H), 8.14 (s, 1H), 13.11 (bs, 1H).
2-(2-(Trifluoromethoxy)benzamido)thiazole-4-carboxylic acid
Ethyl 2-(2-(trifluoromethoxy)benzamido)thiazole-4-carboxylate (10 g, 28 mmol, 1 eq.) was dissolved in THF (20 ml) and an aqueous 2 M NaOH solution (110 ml) was added at room temperature. The reaction mixture was stirred for 24 h at room temperature. THF was removed under reduced pressure. The residual aqueous phase was acidified to pH 1-2 using a 15% aqueous HCl solution. The precipitate was collected by filtration, washed with water and dried. The product was obtained as a white solid (9.3 g, 28 mmol, quant.).
1 H NMR (400 MHz, DMSO-d 6 ): d (ppm) = 7.49-7.59 (m, 2H), 7.70 (dt, J = 7.8, 1.7 Hz, 1H), 7.79 (dd, J = 7.79, 1.7 Hz, 1H), 8.06 (s, 1H), 13.01 (bs, 2H).
Final compounds
N,N-diisopropylethylamine (6.1 g, 47.1 mmol) was added dropwise to a solution of 2-(2-(trifluoromethoxy)benzamido)thiazole-4-carboxylic acid (5.2 g, 15.7 mmol) in 50 ml DMF. Then HBTU (6.2 g, 16.5 mmol) was added at 0°C and the reaction mixture was stirred for 25 min. Methyl 2-amino-1H-benzo[d]imidazole-5-carboxylate (3.0 g, 15.7 mmol) was added portionwise and the reaction mixture was stirred for 16 h. Water (250 ml) was added and the reaction mixture was stirred for 20 min. Then a saturated aqueous NaHCO 3 solution (20 ml) was added and the mixture was stirred for further 20 min. The suspension was filtered and the solid was washed with water and dried. The residue was purified by flash column chromatography on silica (DCM/MeOH 100:0-100:5). All product fractions were collected and concentrated under reduced pressure. The residue was washed with cold MeOH and dried. The product was obtained as a white solid (2.4 g, 4.7 mmol, 30% yield).
1 H NMR (400 MHz, DMSO-d 6 ): d (ppm) = 3.86 (s, 3H), 7. 3H), 7.73 (dt, J = 7.9, 1.5 Hz, 1H), 2H), 8.12 (s, 1H), 8.36 (s, 1H), 11.42 (bs, 1H), 12.54 (bs, 1H), 13.10 (bs, 1H) .
2-(2-(Trifluoromethoxy)benzamido)thiazole-4-carboxylic acid (0.30 g, 0,9 mmol), 5-(methylsulfonyl)-1H-benzo[d]-imidazol-2-amine (0.19 g, 0.9 mmol), HBTU (0.34 g, 0.9 mmol) and DMAP (11 mg, 0.09 mmol) were dissolved in DMF (20 ml). The reaction mixture was stirred for 16 h at 60°C. The reaction mixture was diluted with EtOAc and washed with a saturated aqueous NaHCO 3 solution and a 5% aqueous citric acid solution. The organic phase was dried over MgSO 4 filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC/MS. Only the pure fractions were collected and concentrated under reduced pressure. The product was obtained as a white solid (16 mg, 0.03 mmol, 3% yield).
To a solution of 2-(2-(trifluoromethoxy)benzamido)thiazole-4-carboxylic acid (3.2 g, 9.7 mmol) in DMF (45 ml) HBTU (3.9 g, 10.2 mmol) was added portionwise at 0°C, followed by dropwise addition of N,N-diisopropylethylamine (3.8 g, 29.1 mmol). The cooling bath was removed and the reaction mixture was stirred for 10 min. 1-methyl-1H-benzo [d] imidazol-2-amine (1.5 g, 10.2 mmol) was added portionwise and the reaction mixture was stirred at room temperature for 16 h. An aqueous 1 M NaOH solution was added and the reaction mixture was stirred for 15 min. The mixture was diluted with water (10 ml) and extracted with MTBE. The organic extracts were extracted with an aqueous 1 M NaOH solution. The combined aqueous phases were acidified to pH 1-2 using conc. HCl. The formed precipitate was filtered and washed with PE and dried. The product was obtained as a white solid (3.0 g, 6.5 mmol, 64% yield). 
To a solution of 2-(isonicotinamido)thiazole-4-carboxylic acid (0.4 g, 1.6 mmol) and 6-(trifluoromethyl)-1H-benzo[d]-imidazol-2-amine (0.3 g, 1.6 mmol) in DMF (5 ml) HBTU (0.6 g, 1.6 mmol) and N,N-diisopropylethylamine (0.3 ml, 0.2 g, 1.6 mmol) were added. The reaction mixture was stirred at room temperature for 16 h. All volatiles were removed under reduced pressure. The residue was suspended in water and the solid filtered off. The crude product was purified by preparative HPLC/MS. Only the pure fractions were collected and concentrated under reduced pressure. The product was obtained as a white solid (12 mg, 0.03 mmol, 2% yield).
2-(2-(Trifluoromethoxy
To a solution of 2-(2-(trifluoromethoxy)benzamido)thiazole-4-carboxylic acid (3.4 g, 10.4 mmol) in DMF (50 ml) N,N-diisopropylethylamine (4.0 g, 31.1 mmol) was added dropwise at 0°C followed by the addition of HBTU (4.1 g, 10.9 mmol). After stirring for 15 min at 0°C 6-(trifluoromethyl)-1H-benzo[d]imidazol-2-amine (2.1 g, 10.4 mmol) was added portionwise. The reaction mixture was stirred at room temperature for 16 h. All volatiles were removed under reduced pressure. The residue was dissolved in MTBE and washed with an aqueous 5% citric acid solution. The organic phase was extracted with an aqueous 1 M NaOH solution. The combined aqueous phases were acidified to pH 1-2 using conc. HCl. The formed precipitate was filtered and washed with PE and dried. The product was obtained as a white solid (1.5 g, 2.9 mmol, 28% yield). 1 H NMR (400 MHz, DMSO-d 6 ): d (ppm) = 7. 42-7.49 (m, 1H), 7.51-7.61 (m, 2H), 7.63-7.76 (m, 2H), 7.79-7.86 (m, 1H), 8.38 (s, 1H), 11.38 (bs, 1H), 12.60 (bs, 1H), 13.11 (bs, 1H) .
To a solution of 2-(2-trifluoromethoxy-benzoylamino)-thiazole-4-carboxylic acid (3.0 g, 9.0 mmol) in DMF 5-chloro-6-fluoro-1H-benzo[d]imidazol-2-amine (1.8 g, 9.5 mmol) and N,N-diisopropylethylamine (4.5 ml, 3.5 g, 27.1 mmol) were added. The reaction mixture was cooled to 0°C and HBTU (3.6 g, 9.5 mmol) was added portionwise. The reaction mixture was stirred at room temperature for 16 h. All volatiles were removed under reduced pressure. The residue was washed with a saturated aqueous NaHCO 3 solution, a 5% aqueous citric acid solution and MeOH. The residue was purified by flash column chromatography on silica (DCM/ MeOH 95:5). The product was obtained as a white solid (1.1 g, 2.2 mmol, 24% yield). 
To a solution of 2-(furan-2-carboxamido)thiazole-4-carboxylic acid (80 mg, 0.3 mmol) and 6-(trifluoromethyl)-1H-benzo[d]imidazol-2-amine (68 mg, 0.3 mmol) HBTU (127 mg, 0.3 mmol) and N,N-diisopropylethylamine (117 ll, 0.7 mmol) were added and the reaction mixture was stirred at 85°C for 16 h. The reaction mixture was poured into ice water and the formed precipitate filtered off, washed with water and dried. The product was obtained as a white solid (50 mg, 0.1 mmol, 35% yield).
To a solution of 2-(2-(trifluoromethoxy)benzamido)thiazole-4-carboxylic acid (2.0 g, 6.0 mmol) in DMF (15 ml) N,N-diisopropylethylamine (2.3 g, 18.1 mmol) was added dropwise. The reaction mixture was cooled to 0°C and HBTU (2.4 g, 6.3 mmol) was added portionwise. The reaction mixture was stirred at room temperature for 1 h. Then 1H-benzo[d]imidazol-2-amine (0.8 g, 6.3 mmol) was added portionwise and the reaction mixture was stirred at room temperature for 48 h. An aqueous 1 M NaOH solution (5 ml) was added and the reaction mixture was stirred for 15 min. The mixture was diluted with water (10 ml) and extracted with MTBE. The organic extracts were extracted with an aqueous 1 M NaOH solution. The combined aqueous phases were acidified to pH 1-2 using conc. HCl. The formed precipitate was filtered and washed with PE and dried. The product was obtained as a white solid (1.1 g, 2.4 mmol, 41% yield).
1 H NMR (400 MHz, DMSO-d 6 ): d (ppm) = 7.09-7.17 (m, 2H), 7.44-7.51 (m, 2H), 7.52-7.61 (m, 2H), 7.73 (dt, J = 7.87, 1.77 Hz, 1H), 7.82 (dd, J = 7.58, 1.61 Hz, 1H), 8.27 (s, 1H), 11.91 (bs, 2H), 13.05 (bs, 1H).
2-(2-Trifluoromethoxy-benzoylamino)-thiazole-4-carboxylic acid benzothiazol-2-ylamide (9) 2-(2-(Trifluoromethoxy)benzamido)thiazole-4-carboxylic acid (0.1 g, 0.3 mmol) was dissolved in DMF (3 ml) and N,N-diisopropylethylamine (39 mg, 0.3 mmol) was added. The reaction mixture was stirred for 2 min and HBTU (0.1 g, 0.3 mmol) and benzo[d]thiazol-2-amine (45 mg, 0.3 mmol) were added. The reaction mixture was stirred at 70°C for 16 h. All volatiles were removed under reduced pressure. The residue was dissolved in EtOAc and washed with a 5% aqueous citric acid solution, a saturated aqueous NaHCO 3 solution and water. The organic phase was dried over MgSO 4 , filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (DCM/MeOH 95:5). The product was obtained as a white solid (33 mg, 0.07 mmol, 24% yield 
To a solution of 2-(2-(trifluoromethoxy)benzamido)thiazole-4-carboxylic acid (1.4 g, 4.2 mmol) in DMF (50 ml) N,N-diisopropylethylamine (1.6 g, 12.5 mmol) was added dropwise. The reaction mixture was cooled to 0°C and HBTU (1.7 g, 4.4 mmol) was added portionwise. The reaction mixture was stirred at room temperature for 15 min. Then benzo[d]oxazol-2-amine (0.6 g, 4.4 mmol) was added portionwise and the reaction mixture was stirred at room temperature for 16 h.
All volatiles were removed under reduced pressure. The residue was dissolved in MTBE and washed with an aqueous 5% citric acid solution and a saturated aqueous NaHCO 3 solution. The organic phase was dried over MgSO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica (DCM/MeOH 100:0 to 99:1). The crude product was dissolved in a small amount MeOH and water was added. The precipitate was dried to afford the product as a white solid (750 mg, 1.7 mmol, 40% yield).
1 H NMR (400 MHz, DMSO-d 6 ): d (ppm) = 7.27-7.39 (m, 2H), 7.50-7.76 (m, 5H), 7.81 (d, J = 7.59 Hz, 1H), 8.30 (s, 1H), 11.48 (bs, 1H), 13.08 (bs, 1H).
Plasmids
CK1dTV1 and 2 (transcription variants 1 and 2) were PCR amplified from mouse cDNA (5 0 -primer TV1 and 2:
0 ) and cloned into pcDNA3.1/V5-HisÓ TOPO Ò TA cloning vector (Invitrogen, Karlsruhe, Germany) before being subcloned into pGEX-2T expression vector via BamHI to generate plasmids pGEX-2T-mouse CK1dTV1 (FP1170) and pGEX-2T-mouse CK1dTV2 (FP1171).
For the expression of wt rat CK1d and rat CK1d M82F as glutathione S-transferase fusion proteins the plasmids pGEX-2T-CK1d (FP449) (Knippschild et al. 1997 ) and pGEX-2T-CK1d M82F (FP1153) (Peifer et al. 2009 ) were used. Plasmid pGEX-2T-mouse p53 1-64 was used to express GST-mouse p53 1-64 (FP267) which was used as substrate in in vitro kinase reactions (Milne et al. 1992 ).
Overexpression and purification of glutathione S-transferase fusion proteins
Expression and purification of the GST-fusion proteins GST-mouse p53 1-64 (FP267), GST-rat CK1d (FP449), GST-rat CK1d M82F (FP1153), GST-mouse CK1dTV1 (FP1170), and GST-mouse CK1dTV2 (FP1171) was carried out as described elsewhere (Wolff et al. 2005) . Expression of fusion proteins FP1170 and 1171 was either performed at 37°C for 2 h, or at 15°C for 14 h. FP449 and FP1153 were always expressed at 15°C for 14 h.
In vitro kinase assays
In vitro kinase assays were carried out in the presence of various potential inhibitors of CK1d at an ATP concentration of 0.01 mM and dimethyl sulfoxide (DMSO) solvent control as described previously (Knippschild et al. 1996) . Where indicated higher ATP concentrations (0.05, 0.1, 0.25 and 0.5 mM) were used. The fusion protein GSTmouse p53 1-64 (FP267) was used as substrate. Recombinant CK1d kinase domain (CK1dkd, NEB, Frankfurt am Main, Germany), GST-rat CK1d (FP449), GST-rat CK1d M82F (FP1153), GST-mouse CK1dTV1, GST-mouse CK1dTV2 and recombinant human CK1e (Invitrogen, Karlsruhe, Germany) were used as sources of enzyme. Phosphorylated proteins were separated by SDS-PAGE and the protein bands were visualized on dried gels by autoradiography. The phosphorylated protein bands were excised and quantified by Cherenkov counting.
Phosphopeptide analysis
Phosphopeptide analysis of in vitro labeled proteins was carried out as described previously (Wolff et al. 2005) .
KINOMEscan: high-throughput kinase selectivity profiling KINOMEscan TM was performed to determine binding constants of coumpound 5 to 442 eukaryotic kinases by Ambit Biosciences Cooperation, San Diego, USA.
X-ray analyses
Crelux (CRELUX GmbH, Martinsried, Germany) produced co-crystals of a human truncated mutant casein kinase 1 d (CK1d 1-316, R13N ) with compound 5 that diffract to 1.7 Å resolutions at the ESRF synchrotron radiation source and determined the X-ray structure.
Crystals were obtained using sitting drop vapor diffusion setups. The diluted protein solution (1 mg/ml) was incubated at room temperature for 2 h with 15 mM of compound 5 and then concentrated to 13.5 mg/ml. 0.4 ll of protein solution (13.5 mg/ml in 50 mM HEPES, 200 mM NaCl, 1 mM EDTA, 1 mM DTT, 5 mM b-OG, pH 7.5) was mixed with 0.4 ll of reservoir solution (0.1 M NaCl, 1.4 M (NH 4 ) 2 SO 4 , 0.1 M bis-tris, pH 5.8) and equilibrated over 60 ll of reservoir solution. Crystals appeared after 1-3 days.
The structure was determined by molecular replacement using the published CK1d structure (PDB accession code 1CKI) as search model followed up by refinement of this model with REFMAC5 (Collaborative Computational Project 1994; Murshudov et al. 1996) . Several rounds of alternating manual rebuilding and refinement resulted in the final model.
Modeling M82F mutant and docking
Based on the X-ray structure of human CK1d (Kit et al. 1969)] were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal calf serum (FCS; Biochrom, Berlin, Germany). The fibrosarcoma cell line HT1080 (Rasheed et al. 1974 ) was grown in DMEM containing 10% FCS and 2 mM glutamine while both the prostate cancer cell line DU-145 (Stone et al. 1978 ) and the ovary tissue cancer cell line OVCAR-3 (Hamilton et al. 1983) were maintained in RPMI-1640 supplemented with 10% FCS. The pancreatic cancer cell line Colo357 (Morgan et al. 1980 ) was grown in DMEM/RPMI (1:1) and the colon adenocarcinoma cell line SW480 (Leibovitz et al. 1976 ) in Leibovitz L-15 medium, both containing 10% FCS and 2 mM glutamine. All media were supplemented with 100 U/ml penicillin and 100 lg/ml streptomycin (Gibco, Karlsruhe, Germany) and all cell lines were grown at 37°C in a humidified 5% carbon dioxide atmosphere.
Flow cytometry and cell cycle analysis Subconfluent Frwt648, mKSA, Colo357, OVCAR-3, HT1080, DU-145 and SW480 cells were treated with 2 or 4 lM of compounds 5 or 6 for 48 h. Untreated and DMSO treated cells served as control. Cells were harvested, washed once with phosphate-buffered saline (PBS), and prepared for cell cycle analysis using the ''Cycle Test Plus Kit'' (BD, San Jose, USA). Cell cycle profiles were obtained using a FACScan flow cytometer and CellQuest software (BD Biosciences, San Jose, USA).
Results
Biological activity of new identified compounds
Compounds 1-10 (Table 1) were initially assayed for their biological activity against CK1dkd and CK1e at a concentration of 10 lM ATP (Fig. 1a, b) . Compounds 4, 5 and 6, which showed significant inhibition of CK1dkd and CK1e in these assays were further characterized for their IC 50 values against CK1dkd, GST-rat CK1d, GST-mouse CK1dTV1, GST-mouse CK1dTV2 and human CK1e (Table 2) . Differences in the IC 50 values of compounds 4, 5 and 6 against CK1d transcription variants could be due to their differences in amino acid composition and the degree of site-specific phosphorylation within their C-terminal regulatory domains. This prediction is underlined by two dimensional phosphopeptide analyses showing quantitative and qualitative differences in the degree of phosphorylation of CK1dTV1 and CK1dTV2 (Fig. 2) . Furthermore, induction of recombinant CK1d transcription variants in bacteria at different temperatures influences its phosphorylation status, activity and sensibility towards small molecule inhibitors (Fig. 3) . CK1d transcription variants induced at 15°C for 14 h are more active and incorporate more radioactive phosphate in the substrate than CK1d transcription variants induced at 37°C for 2 h (Fig. 3a) . Lower degree of phosphorylation of both transcription variants increases the ability of compound 5 to inhibit substrate phosphorylation of both transcription variants indicated by their 1.5-to 2-fold lower IC 50 values (Fig. 3b) .
Selectivity profiling of compound 5 in a panel of 442 protein kinases
In order to investigate the specificity of compound 5 its ability to inhibit other kinases at a concentration of 10 lM a KINOMEscan TM (KINOMEscan, San Diego, USA) with a panel of 442 protein kinases was performed (Fig. 4) . In this assay CK1 isoforms were potentially inhibited by compound 5 (CSNK1E 0.35%, CSNK1D 2% and CSNK1A1 3% remaining kinase activity relative to controls), while most kinases were not affected significantly. However, in the presence of compound 5 (10 lM) the kinase activities of few kinases were similarly low, among them CLK1 (2.6%), DYRK1A (4.1%), CLK4 (7.2%), DYRK1B (6.6%), and PIP5K2C (9.6%).
Binding mode of compound 5 to CK1d
The tertiary structure of the protein is well conserved in comparison with 1CKI. The DFG-motiv exhibits the 'in'-conformation (Pargellis et al. 2002) . Compound 5 binds to the ATP-site as depicted in Fig. 5 . The sidechain conformation of gatekeeper methionine 82 is more compact to accommodate the trifluoromethyl-group but no deeper/ selectivity pocket is opened. Hinge residues leucine 84 and leucine 85 are hydrogen bonded via the backbone carbonyl to NH and the backbone nitrogen to the imidazole nitrogen of compound 5, respectively. CH/p-bonds are formed for all three aromatic regions of compound 5. Hydrophobic interactions exist between the trifluoromethoxy-group and In order to prove these compounds as ATP competitive inhibitors, 4, 5 and 6 were tested at their IC 50 concentrations for the potency to inhibit CK1dkd in the presence of different amounts of ATP (Fig. 6a-c) . Since the IC 50 values increased progressively upon raising the concentration of ATP the ATP competitive properties of all tested compounds were confirmed. This finding underlines and clearly shows that 4, 5 and 6 are highly potent inhibitors of CK1d which are able to bind and block kinase activity even in the presence of increased ATP concentrations.
Inhibitory effects of compounds 4, 5 and 6 on GST-wt CK1d and GST-CK1d
M82F
Previously it has been shown that methionine 82 plays an important role as gatekeeper residue in the docking mode of isoxazoles to the ATP binding pocket since mutation of methionine 82 to phenylalanine blocks binding of this class of CK1d specific inhibitors (Peifer et al. 2009 ) while still binding ATP. Therefore, we now analyzed the effects of exchanging methionine 82 to phenylalanine on the ability of compounds 4, 5 and 6 to inhibit CK1d activity. In vitro kinase assays were performed in the absence and presence of 4, 5 and 6 at their determined IC 50 concentrations using GST-wt CK1d or GST-CK1d M82F as the source of enzyme. GST-wt CK1d activity was clearly decreased in the presence of 4, 5 and 6. Interestingly, in comparison with inhibition of GST-wt CK1d the kinase activity of GSTCK1d M82F was much more affected in reactions containing compounds 4 or 5, but similarly or even less affected by compound 6 (Fig. 7 ). These observations underline the different binding mode of these compounds than that of Fig. 2 Comparison of the phosphorylation of mouse CK1dTV1 and TV2. Purified GST-mouse CK1dTV1 and GST-mouse CK1dTV2 were autophoshorylated in vitro for 30 min. Phosphorylated proteins were separated by SDS-PAGE, blotted onto PVDF membranes, trypsinized and oxidized. The resulting phosphopeptides were separated in two dimensional analyses by electrophoresis at pH 1.9 and ascending chromatography. Phosphopeptides were labeled with capital letters. Phospopeptides H, J, K, L, and M were only present in CK1dTV1, whereas except G and I all other phosphopeptides (A, B, C, D, E, and F) of CK1dTV1 were reduced in comparison to those of CK1dTV2 isoxazoles, which address the selectivity pocket, while compounds 4-6 do not bind to this region in the active site.
Differences in ligand interaction of compounds 4, 5 and 6 in wt CK1d and CK1d
Docking poses in wt CK1d and CK1d M82F align well with the X-ray determined pose of compound 5 in the wild type. Mutation of methionine 82 has nearly no influence on the docking pose, although the cavity for the ligand is marginally reduced. For compounds 4 and 5 the synthesized [1H] benzimidazole tautomers exhibit a better docking score than the [3H] tautomers 4b and 5b, whereas the [3H] tautomer 6b scores better than the synthesized compound 6. As tautomerism within the assay cannot be excluded, both tautomers for compound 6 were optimized and rescored. Regardless of tautomerism, the NH Leu85 ÁÁÁN Benzimidazol hydrogen bond is always formed (Fig. 5) , resulting in a flip of the benzimidazole ring and thus a different orientation of the attached functional groups. However, in all cases the docking scores for compounds 4 and 5 in CK1d
M82F improve compared to wt CK1d whereas compounds 6 and 6b fall off and are thus in accordance with the experimental results (Table 3 ). The differences can be explained by the p-hydrogen bond between benzimidazole and phenylalanine 82, which is not possible for both tautomers of compound 6. The necessary hydrogen is substituted with fluorine or chlorine, respectively (Fig. 8) .
Efficacy of 5 and 6 in cell culture Although potent inhibition of CK1d has been observed for several inhibitor compounds in vitro, these might not necessarily show similar effects in in vivo experiments. In order to identify inhibitors which are able to pass cell membranes and inhibit proliferation of tumor cell lines, a panel of seven cell lines (Frwt648, mKSA, Colo357, OV-CAR-3, HT1080, DU-145 and SW480) was either treated with 2 or 4 lM of compounds 5 or 6 (or with DMSO as a negative control) for 48 h. FACS analyses were performed to compare the effects of both compounds with those of vehicle only (DMSO) with respect to cell viability and cell cycle distribution. Our results indicated that the SV40-transformed Frwt648 and mKSA cell lines are highly sensitive towards treatment with 2 and 4 lM of compounds 5 and 6 (35-98% dead cells; Fig. 9 ). Similar, but significantly weaker effects could be observed for cell lines HT1080, DU-145 and SW480 after 48 h treatment with compounds 5 and 6 (data not shown). However, no measurement using these three cell lines detected more than 20% of dead cells with DU-145 even being unsusceptible to treatment with compound 5 (data not shown). In addition to the increased amount of dead cells after 48 h treatment of Colo357 cells with compounds 5 and 6, more cells appeared to be in the G1 phase of the cell cycle (Fig. 9) . OVCAR-3 cells were more sensitive to compound 6 in the tested concentrations as 22, and 39%, respectively, of the cells died upon treatment. Treatment of OVCAR-3 cells with compound 5 resulted in a slight increase of cells in the G2 phase of the cell cycle (Fig. 9) . In general, results of this screening show cell line specific differences in the potency of the tested inhibitors to induce apoptosis or cell cycle arrest.
Discussion
Recently, it has become practice to screen cellular pathways in whole cell systems with chemical libraries and then find the cellular target by proteomics or biochemical methods. We have screened for NFjB inhibitors and found hits with Residues within 4.5 Å of compound 5 are fully shown, whereas the backbone is visualized in parts, color-coded for the kinase-typical structural elements (aC green, gatekeeper orange, hinge-region red, gylcine-rich loop blue and DFG-motif yellow (background)). The doted lines depict hydrogen bonds in cyan for standard and orange for p-hydrogen bonds nanomolar activity. These compounds were piperidinothiazole carboxylamido-benzimidazoles (Leban et al. 2007) . The NFjB pathway is complex and contains many possible targets for inhibition. We therefore further investigated the mechanism of action of these compounds and established that the inhibition of NFjB is derived from the multiple kinase inhibition profile.
To further improve the physicochemical properties of the series we deleted the piperidino part of the molecule and derived at acylaminobenzothiazolocarboxamidobenzothiazoles as exemplified by compounds 1-10 in Table 1 .
The compounds were tested in kinase assays using a CK1 specific substrate as described. The parent compound 9 had only moderate but significant effects on CK1dkd (IC 50 = 1.116 lM). When the benzimidazole NH was replaced by S (as in compound 10) or O (as in compound 11), kinase activity was even more decreased. When the NH of the benzimidazole was blocked by methylation in compound 3 activity against CK1dkd was lost. An improvement of activity was obtained when a hydrophobic trifluoromethyl residue was introduced into the benzimidazole in compound 5 (IC 50 CK1dTV1 = 0.022 lM). Similarily, hydrophobic halogen residues in 6 lead to good activity with an IC 50 of 0.048 lM for CK1dTV1. If one compares compound 5 with compounds 4 and 7 it is obvious that the trifluoromethoxyphenylacyl on the aminobenzothiazole is optimal. Hydrophylic groups on the benzimidazole as in compound 1 and 2 lead to diminished activity. The SAR presented is in good agreement with the X-ray structure results and fully explains most interactions found.
Although some isoform selective effects of the tested molecules could be observed, especially for compound 5 (up to 7-fold more active on CK1dkd compared to CK1e), in the concentration range which is commonly used and necessary for cell-based screening and therapeutic application, isoform selectivity will not be observed. Being highly conserved within the kinase domain, the CK1 isoforms significantly differ in their N-and C-terminal domains. According to our results inhibitory (auto-)phosphorylation within the C-terminal regulatory domain not only influences kinase activity but also the effect of inhibitor molecules. When kinase proteins are expressed for 14 h at 15°C C-terminal phosphorylation is reduced leading to increased kinase activity and more potent inhibitor action. Increased C-terminal phosphorylation comes along with less potent action of inhibitor molecules. This observation could be explained by inhibitor compounds competing with the C-terminal domain which can act as pseudo-substrate thereby possibly blocking the catalytic center of the kinase (Gietzen and Virshup 1999; Rivers et al. 1998) .
According to the data obtained from the selectivity profiling also CK1 isoforms a and c turned out to be targets of at least compound 5. However, effects of the molecules presented in this study have not yet been tested on CK1a and c.
For the three most effective compounds the postulated binding to the CK1d protein was validated in vitro. The Fig. 6 Compounds 4, 5 and 6 inhibit CK1d in an ATP competitive manner. Inhibitors 4 (a; 380 nM), 5 (b; 30 nM) and 6 (c; 85 nM) were assayed in the presence of the indicated ATP concentrations. Kinase assays were perfomed using CK1dkd as enzyme and GST-p53 fusion protein (FP267) as substrate. Kinase activity in reactions containing inhibitor was calculated relative to the control reaction for each ATP concentration. While ATP concentrations increase, incorporation of radioactive labeled phosphate into substrate FP267 decreases, leading to weakened signals in the autoradiographs first approach clearly confirmed the ATP competitive properties of the tested compounds since inhibitory effects are disappearing along with increasing ATP concentration. The second approach, using the CK1d M82F gatekeeper mutant, is some more sophisticated. The ATP binding site is highly conserved among most protein kinases. However, access of the ligand to the hydrophobic binding pocket can be tightly controlled by various gatekeeping amino acid residues. If these residues get mutated, substrate phosphorylation and also inhibitor action can be affected (Elphick et al. 2007 ). In the case of rat CK1d the gatekeeping residue is methionine 82 which was mutated to the more bulky phenylalanine in order to ''close the gate'' to the kinase's selectivity pocket (Oumata et al. 2008; Peifer et al. 2009 ). According to our predictions and X-ray models, the tested compounds are not occupying the selectivity pocket. Therefore, in spite of the ''closed gate'', 4 and 5 inhibited the activity of CK1d M82F better than that of wt CK1d because of an additional p-hydrogen bond to phenylalanine 82.
In a final biological screen we demonstrated, that compounds 5 and 6 are able to negatively affect the proliferation of several tumor cell lines. Although our cell cycle analysis shows significant effects, we have to take into account that isoforms of the CK1 family of protein kinases are involved in numerous cellular signalling pathways. Thus consideration of the cellular background is crucial for evaluation of any results. In order to get a more detailed insight to affected Fig. 7 Inhibition of GST-wt CK1d and a GST-CK1d M82F gatekeeper mutant. a Compounds 4 (0.313 lM), 5 (0.039 lM) and 6 (0.156 lM) were assayed for their ability to inhibit GST-wt CK1d in comparison to a GST-CK1d M82F gatekeeper mutant using GST-p53 1-64 fusion protein (FP267) as substrate. GST-CK1d
M82F shows stronger inhibition of kinase activity in the presence of compounds 4 and 5 and a lower inhibition in the presence of compound 6 than GST-wt CK1d. b Kinase activity is presented as bar graph normalized towards solvent controls (right). The hinge-region is marked red and the gatekeeper orange. The p-hydrogen bonds discerning the compounds in inihibition strength are dotted orange Fig. 9 Cell cycle analysis of selected cell lines after treatment with compounds 5 and 6 Cell cycle analysis of Frwt648, mKSA, Colo357 and OVCAR-3 cells treated with compounds 5 and 6 (2 or 4 lM) for 48 h. Cells were stained with propidium iodide and analyzed using a flow cytometer. Control cells were treated with DMSO. The SV40-transformed Frwt648 and mKSA cells were highly sensitive towards treatment with 5 and 6. Additionally to the increased amount of dead cells treatment of Colo357 also resulted in more cells in G1 phase of the cell cycle and treatment of OVCAR-3 also slightly increased the amount of cells in G2 phase c cellular pathways and functions, more complex approaches for cell culture based profiling are needed.
In conclusion we designed and characterized new inhibitor compounds with remarkable selectivity towards CK1d and e.
